翰宇药业 (300199)
Hybio Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 88324.13
- Circulating A-Shares(W): 74569.78
- Earnings Per Share(RMB): 0.0800
- Net Assets Per Share(RMB): 0.7350
- Operating Revenue(W RMB): 68312.29
- Total Profit(W RMB): 8761.37
- Net Profit Attributable to Parent(W RMB): 7135.15
- Net Profit Growth Rate(%): 305.00
- Weighted Return on Equity(%): 11.6200
- Operating Cash Flow Per Share(RMB): 0.3070
- Undistributed Profit Per Share(RMB): -2.0142
- Capital Reserve Per Share(RMB): 1.6392
2. Main Business
The main business covers:
- Peptide Preparations
- Peptide APIs
- Small Nucleic Acids
- CDMO/CMO
3. Company Basic Information
- Company Name: Hybio Pharmaceutical Co., Ltd.
- Listing Date: 2011-04-07
- Industry: Pharmaceutical Manufacturing
- Address: Hybio Innovation Industry Building, No.7 Guansheng 4th Road, Guanlan High-tech Park, Longhua District, Shenzhen, Guangdong Province, China
- Website: www.hybio.com.cn
- Company Profile：The company was formerly known as Shenzhen Hybio Pharmaceutical Co., Ltd., established on April 2, 2003. It was restructured into Hybio Pharmaceutical Co., Ltd. on September 3, 2009, and listed on the Shenzhen Stock Exchange ChiNext board on April 7, 2011. It is a national high-tech enterprise focusing on the R&D, production, and sales of peptide drugs.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 3354.79 | 4.50 |
| 2 | China Merchants Securities International Co., Ltd. - Client Funds | General Legal Person | 419.75 | 0.56 |
| 3 | Tibet Rongrui Investment Co., Ltd. | General Legal Person | 316.00 | 0.42 |
| 4 | China Merchants CSI 500 Equal Weight Index Enhanced Securities Investment Fund Class A | Fund | 18.10 | 0.02 |
5. Concept Sectors
- Venture Capital
- Biological Vaccine
- Infant & Child Concept
- Guangdong-Hong Kong-Macao Greater Bay Area
- Immunotherapy
- Smart Healthcare
- Blockchain
- Artificial Intelligence
- Industrial Hemp
- Mask Protection
- CXO Concept
- NMN Concept
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- Weight Loss Drugs
- Synthetic Biology
- AI Healthcare
- Margin Trading & Securities Lending
- High Price-to-Book Ratio
- Private Placement Plan
- Investing in Newly Listed Companies
- Consecutive Losses
- Increasing Number of Shareholders
- Overseas Business
- ChiNext 300
- ChiNext Pharmaceuticals
- ChiNext 200
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information